Description of the active substance:
This information is a reference and it is not enough that the drug has been prescribed by a doctor ..
PHARMACHOLOGIC EFFECT
Anxiolytic agent, tetramethyltetraazabicyclooctanedione. Has also an anticonvulsant effect. Not giving a direct sleeping pills, regulates disturbed sleep at night. Does not show central or peripheral cholinoblocking properties. Anxiolytic action is not accompanied by muscle relaxation and violation of coordination of movements.
PHARMACOKINETICS
It is excreted by the kidneys within 24 hours after administration.
INDICATIONS
Neuroses and neurosis-like conditions (irritability, emotional lability, anxiety, fear). Anxiety and paranoid syndrome in schizophrenia, involutional and vascular psychoses. Chronic verbal hallucinosis of organic genesis. Complex therapy for the treatment of patients with cardialgia, ischemic heart disease and rehabilitation after myocardial infarction. Decreased craving for smoking tobacco, ethanol, psychoactive drugs; improving the tolerability of neuroleptics and tranquilizers.
DOSING MODE
Apply inside 0.3-1 g 2-3 times / day (regardless of food intake). The maximum single dose - 3 grams, daily - 10 g. The course of treatment - up to 2-3 months, with mental illness - up to 6 months.
SIDE EFFECT
Perhaps: allergic reactions (skin itching), lowering blood pressure, hypothermia (at 1-1.5 В° C), dyspepsia.
CONTRAINDICATIONS
Hypersensitivity to mebikara.
SPECIAL INSTRUCTIONS
Decrease in blood pressure and body temperature is not a reason for the abolition of therapy and normalizes independently.
Impact on the ability to drive vehicles and manage mechanisms
During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
DRUG INTERACTION
Strengthens the effect of hypnotics.
